SLC6A14 is a genetic modifier of cystic fibrosis that regulates pseudomonas aeruginosa attachment to human bronchial epithelial cells

mBio

Volumn 8, Issue 6, 2017, Pages

  Di Paola, Michelle ^a,b   Park, Amber J ^c   Ahmadi, Saumel ^a,b   Roach, Elyse J ^c   Wu, Yu Sheng ^a,b   Struder Kypke, Michaela ^c   Lam, Joseph S ^c   Bear, Christine E ^a,b   Khursigarac, Cezar M ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Airway epithelia; Bacterial colonization; CFTR mutation; Cystic fibrosis; L arginine uptake; Modifier gene; Pseudomonas aeruginosa; SLC6A14

Indexed keywords

ARTICLE; BACTERIAL ATTACHMENT; BACTERIAL COLONIZATION; BACTERIAL PHENOMENA AND FUNCTIONS; BRONCHUS EPITHELIUM; CFTR GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIATION; HEREDITY; HUMAN; HUMAN CELL; LUNG FIBROSIS; MODIFIER GENE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; SLC6A14 GENE; UPREGULATION; ANIMAL; BACTERIUM ADHERENCE; COMPLICATION; CYSTIC FIBROSIS; DEFICIENCY; EPITHELIUM CELL; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTION;

AMINO ACID TRANSPORTER; ARGININE; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORTER; SLC6A14 PROTEIN, HUMAN; SLC6A14 PROTEIN, MOUSE;

AMINO ACID TRANSPORT SYSTEMS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; ARGININE; BACTERIAL ADHESION; CYSTIC FIBROSIS; EPITHELIAL CELLS; HUMANS; MICE, KNOCKOUT; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85039907250     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02073-17     Document Type: Article

References (42)

1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059-1065. https://doi.org/10.1126/science.2772657.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073. https://doi.org/10.1126/science.2475911.
3. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080. https://doi.org/10.1126/science.2570460.
4. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222. https://doi.org/10.1128/CMR.15.2.194-222.2002.
5. Stoltz DA, Meyerholz DK, Welsh MJ. 2015. Origins of cystic fibrosis lung disease. N Engl J Med 372:351-362. https://doi.org/10.1056/NEJMra1300109.
6. Shah VS, Meyerholz DK, Tang XX, Reznikov L, Abou Alaiwa MA, Ernst SE, Karp PH, Wohlford-Lenane CL, Heilmann KP, Leidinger MR, Allen PD, Zabner J, McCray PB, Ostedgaard LS, Stoltz DA, Randak CO, Welsh MJ. 2016. Airway acidification initiates host defense abnormalities in cystic fibrosis mice. Science 351:503-507. https://doi.org/10.1126/science.aad5589.
7. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR, Gene Modifier Study Group. 2005. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443-1453. https://doi.org/10.1056/NEJMoa051469.
8. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW, Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Paré P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O’Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR. 2011. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539-546. https://doi.org/10.1038/ng.838.
9. Corvol H, Blackman SM, Boëlle PY, Gallins PJ, Pace RG, Stonebraker JR, Accurso FJ, Clement A, Collaco JM, Dang H, Dang AT, Franca A, Gong J, Guillot L, Keenan K, Li W, Lin F, Patrone MV, Raraigh KS, Sun L, Zhou Y-H, O'Neal WK, Sontag MK, Levy H, Durie PR, Rommens JM, Drumm ML, Wright FA, Strug LJ, Cutting GR, Knowles MR. 2015. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun 6:8382. https://doi.org/10.1038/ncomms9382.
10. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson PF, Parekh RV, Zelenika D, Blackman SM, Corey M, Doshi VK, Henderson L, Naughton KM, O’Neal WK, Pace RG, Stonebraker JR, Wood SD, Wright FA, Zielenski J, Clement A, Drumm ML, Boëlle PY, Cutting GR, Knowles MR, Durie PR, Strug LJ. 2012. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44:562-569. https://doi.org/10.1038/ng.2221.
11. Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, Sun L, Strug LJ. 2014. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet 133:151-161. https://doi.org/10.1007/s00439-013-1363-7.
12. Galietta LJ, Musante L, Romio L, Caruso U, Fantasia A, Gazzolo A, Romano L, Sacco O, Rossi GA, Varesio L, Zegarra-Moran O. 1998. An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells. Am J Physiol 275:L917-L923.
13. Palmer KL, Mashburn LM, Singh PK, Whiteley M. 2005. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 187:5267-5277. https://doi.org/10.1128/JB.187.15.5267-5277.2005.
14. Bernier SP, Ha DG, Khan W, Merritt JH, O’Toole GA. 2011. Modulation of Pseudomonas aeruginosa surface-associated group behaviors by individual amino acids through c-di-GMP signaling. Res Microbiol 162:680-688. https://doi.org/10.1016/j.resmic.2011.04.014.
15. Babu E, Bhutia YD, Ramachandran S, Gnanaprakasam JP, Prasad PD, Thangaraju M, Ganapathy V. 2015. Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer. Biochem J 469:17-23. https://doi.org/10.1042/BJ20150437.
16. Karunakaran S, Ramachandran S, Coothankandaswamy V, Elangovan S, Babu E, Periyasamy-Thandavan S, Gurav A, Gnanaprakasam JP, Singh N, Schoenlein PV, Prasad PD, Thangaraju M, Ganapathy V. 2011. SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem 286:31830-31838. https://doi.org/10.1074/jbc.M111.229518.
17. Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK, Reynolds CP, Yang S, Ogura J, Ganapathy V, Bhutia YD. 2016. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol 173:3292-3306. https://doi.org/10.1111/bph.13616.
18. Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. 2006. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res 23:1482-1490. https://doi.org/10.1007/s11095-006-0255-0.
19. Harrison F, Muruli A, Higgins S, Diggle SP. 2014. Development of an ex vivo porcine lung model for studying growth, virulence, and signaling of Pseudomonas aeruginosa. Infect Immun 82:3312-3323. https://doi.org/10.1128/IAI.01554-14.
20. Flach CF, Qadri F, Bhuiyan TR, Alam NH, Jennische E, Holmgren J, Lönnroth I. 2007. Differential expression of intestinal membrane transporters in cholera patients. FEBS Lett 581:3183-3188. https://doi.org/10.1016/j.febslet.2007.06.001.
21. Eriksson A, Flach CF, Lindgren A, Kvifors E, Lange S. 2008. Five mucosal transcripts of interest in ulcerative colitis identified by quantitative real-time PCR: a prospective study. BMC Gastroenterol 8:34. https://doi.org/10.1186/1471-230X-8-34.
22. Anderson GG, Moreau-Marquis S, Stanton BA, O’Toole GA. 2008. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76:1423-1433. https://doi.org/10.1128/IAI.01373-07.
23. Everett J, Turner K, Cai Q, Gordon V, Whiteley M, Rumbaugh K. 2017. Arginine is a critical substrate for the pathogenesis of Pseudomonas aeruginosa in burn wound infections. mBio 8:e02160-16. https://doi.org/10.1128/mBio.02160-16.
24. Grasemann H, Ratjen F. 2012. Nitric oxide and l-arginine deficiency in cystic fibrosis. Curr Pharm Des 18:726-736. https://doi.org/10.2174/138161212799315911.
25. Saiman L, Cacalano G, Gruenert D, Prince A. 1992. Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immun 60:2808-2814.
26. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O’Toole GA, Stanton BA. 2008. The ΔF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 295:L25-LL37. https://doi.org/10.1152/ajplung.00391.2007.
27. Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O’Toole GA. 2012. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother 67:2673-2681. https://doi.org/10.1093/jac/dks296.
28. Pezzulo AA, Tang XX, Hoegger MJ, Abou Alaiwa MHA, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Bánfi B, Horswill AR, Stoltz DA, McCray PB, Welsh MJ, Zabner J. 2012. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487:109-113. https://doi.org/10.1038/nature11130.
29. Sriramulu DD, Lünsdorf H, Lam JS, Römling U. 2005. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol 54:667-676. https://doi.org/10.1099/jmm.0.45969-0.
30. Landry RM, An D, Hupp JT, Singh PK, Parsek MR. 2006. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol Microbiol 59:142-151. https://doi.org/10.1111/j.1365-2958.2005.04941.x.
31. Matsui H, Wagner VE, Hill DB, Schwab UE, Rogers TD, Button B, Taylor RM, Superfine R, Rubinstein M, Iglewski BH, Boucher RC. 2006. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 103:18131-18136. https://doi.org/10.1073/pnas.0606428103.
32. Hendricks MR, Lashua LP, Fischer DK, Flitter BA, Eichinger KM, Durbin JE, Sarkar SN, Coyne CB, Empey KM, Bomberger JM. 2016. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc Natl Acad Sci U S A 113:1642-1647. https://doi.org/10.1073/pnas.1516979113.
33. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 13:572-581. https://doi.org/10.1099/00221287-13-3-572.
34. Winstanley C, O’Brien S, Brockhurst MA. 2016. Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol 24:327-337. https://doi.org/10.1016/j.tim.2016.01.008.
35. Mahenthiralingam E, Campbell ME, Speert DP. 1994. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 62:596-605.
36. Taylor RF, Hodson ME, Pitt TL. 1993. Adult cystic fibrosis: association of acute pulmonary exacerbations and increasing severity of lung disease with auxotrophic mutants of Pseudomonas aeruginosa. Thorax 48:1002-1005. https://doi.org/10.1136/thx.48.10.1002.
37. Fothergill JL, Mowat E, Ledson MJ, Walshaw MJ, Winstanley C. 2010. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol 59:472-481. https://doi.org/10.1099/jmm.0.015875-0.
38. Barth AL, Pitt TL. 1995. Auxotrophic variants of Pseudomonas aeruginosa are selected from prototrophic wild-type strains in respiratory infections in patients with cystic fibrosis. J Clin Microbiol 33:37-40.
39. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. https://doi.org/10.1006/meth.2001.1262.
40. Ward LD, Kellis M. 2016. HaploReg v4: Systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res 44:D877-D881. https://doi.org/10.1093/nar/gkv1340.
41. Nivens DE, Ohman DE, Williams J, Franklin MJ. 2001. Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol 183:1047-1057. https://doi.org/10.1128/JB.183.3.1047-1057.2001.
42. O’Toole GA. 2011. Microtiter dish biofilm formation assay. J Vis Exp 47:2437. https://doi.org/10.3791/2437.